Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Debt: 2013-2025

Historic Non-Current Debt for China Pharma Holdings (CPHI) over the last 4 years, with Jun 2025 value amounting to $1.3 million.

  • China Pharma Holdings' Non-Current Debt fell 5.93% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.3 million, marking a year-over-year decrease of 5.93%. This contributed to the annual value of $1.4 million for FY2024, which is 1.47% down from last year.
  • As of Q2 2025, China Pharma Holdings' Non-Current Debt stood at $1.3 million, which was down 5.25% from $1.4 million recorded in Q1 2025.
  • In the past 5 years, China Pharma Holdings' Non-Current Debt registered a high of $1.4 million during Q3 2024, and its lowest value of $325,072 during Q2 2021.
  • Its 3-year average for Non-Current Debt is $1.4 million, with a median of $1.4 million in 2024.
  • In the last 5 years, China Pharma Holdings' Non-Current Debt slumped by 83.56% in 2021 and then climbed by 2.46% in 2024.
  • China Pharma Holdings' Non-Current Debt (Quarterly) stood at $325,072 in 2021, then reached $1.4 million in 2023, then declined by 1.47% to $1.4 million in 2024, then dropped by 5.93% to $1.3 million in 2025.
  • Its Non-Current Debt was $1.3 million in Q2 2025, compared to $1.4 million in Q1 2025 and $1.4 million in Q4 2024.